GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sofgen Pharma PROCF · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.03

—

Close of 29 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$373.8m

FY2019FY2024

Net income

−$68.3m

FY2019FY2024

Free cash flow

$63.4m

FY2019FY2024

Shareholders' equity

−$51.1m

FY2019FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$373.8m$423.7m$403.2m$403.7m$331.5m$324.8m
Gross profit$191.5m$238.0m$235.1m$230.1m$191.3m$182.5m
Operating income−$32.5m$44.3m$36.3m$65.1m$63.1m$37.4m
Net income−$68.3m$40.3m$36.1m−$107.0m−$10.4m−$17.0m
Diluted earnings per share-0.610.360.32-0.95-0.09-0.15

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$411.7m$472.5m$442.5m$450.3m$359.5m—
Cash and short-term investments————$4.2m—
Total liabilities$463.8m$473.2m$479.7m$520.3m$615.0m—
Debt$41.4m$31.1m$29.2m$29.0m$454.5m—
Shareholders' equity−$51.1m$210,000−$36.2m−$69.0m−$255.5m—
Shares outstanding113m113m113m113m113m113m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations$88.4m$107.6m$15.6m$35.5m—$68.3m
Capital spending−$25.0m−$32.8m−$34.1m−$25.8m—−$19.7m
Free cash flow$63.4m$74.8m−$18.6m$9.6m—$48.6m

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022
Revenue$118.4m$110.1m$84.2m$101.5m$110.4m$112.4m$85.6m
Gross profit$68.4m$61.2m$46.1m$52.3m$67.6m$72.6m$47.1m
Operating income$13.2m$15.1m$3.3m$2.2m$17.3m$18.1m$2.4m
Net income$8.2m$27.0m$6.6m$10.4m$22.6m−$6.9m$16.4m
Diluted earnings per share0.080.270.070.100.22-0.070.16
Cash from operations$47.0m$20.0m$3.0m−$7.0m$5.0m$9.0m$6.0m
Capital spending−$7.0m−$7.0m−$4.0m−$8.0m−$7.0m−$11.0m−$4.0m
Free cash flow$40.0m$13.0m−$1.0m−$15.0m−$2.0m−$2.0m$2.0m
Total assets$498.6m$490.7m$441.7m$460.2m$471.2m$470.2m$483.3m
Cash and short-term investments$25.8m$20.0m$23.0m$43.0m$27.2m$37.6m$65.6m
Debt$220.7m$170.0m$150.0m$28.4m$170.8m$181.8m$168.6m
Shareholders' equity$39.4m$33.0m$6.1m−$900,000−$9.6m−$28.6m−$18.7m

Financial ratios

Data as of 5 Nov 2026

FY2024FY2023FY2022FY2021
Gross margin51.2%56.2%58.3%57.0%
Operating margin-11.3%20.5%18.3%-2.1%
Net margin-18.3%9.5%9.0%-26.5%
Return on equity133.6%19211.0%-99.8%155.0%
Return on assets-16.6%8.5%8.2%-23.8%
Free cash flow yield3135.1%———
Revenue growth-11.8%5.1%-0.1%—
Earnings growth-269.3%11.7%-133.8%—
Current ratio0.52x0.64x0.72x0.80x
Debt to equity-0.81x148.16x-0.81x-0.42x
Equity ratio-12.4%0.0%-8.2%-15.3%
Interest coverage-0.99x2.13x2.85x-0.10x

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.5%2.8%—
Net income-13.9%32.1%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin53.8%55.8%56.1%—
Operating margin1.5%7.1%9.5%—
Net margin-3.5%-6.2%-5.6%—

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021
Price to earnings-0.10.10.1-0.1
Price to sales0.00.00.00.0

Market value over time

30 Apr 2026 to 3 Nov 2026, in USD

$58.4m$58.2m

Share price return

Finished calendar years

20252024202320222021
Return-92%59%-51%-35%-2%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 30 Sept 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.